Detailed view for TGME49_203390

Basic information

TDR Targets ID: 259037
Toxoplasma gondii, CRAL/TRIO domain-containing protein
Source Database / ID:  ToxoDB 

pI: 4.9823 | Length (AA): 456 | MW (Da): 50481 | Paralog Number: 1

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0

Druggability Group : DG5

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF00650   CRAL/TRIO domain

Gene Ontology

Mouse over links to read term descriptions.
No GO information for this protein.

Metabolic Pathways

This gene is not mapped to any metabolic pathway in KEGG.

Structural information

Modbase 3D models:

There are 4 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
179 419 1r5l (A) 33 275 18.00 0 1 0.73 -0.92
131 426 4j7q (A) 24 323 24.00 0.0000000026 1 0.910823 -0.02
194 395 4tlg (A) 34 246 21.00 0.000013 1 0.718682 -0.56
194 392 4tlg (A) 34 243 29.00 0.000000041 1 0.671104 0.09

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Upper 80-100% percentile VEG Tachyzoite, ME49 Tachyzoite, ME49 merozoite, ME49 Oocyst, ME49 Bradyzoite. Gregory Hehl AB Fritz HM Sibley/Greg
Show/Hide expression data references
  • Gregory ToxoDB
  • Fritz HM Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts.
  • Sibley/Greg ToxoDB
  • Hehl AB Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes.

Orthologs

Ortholog group members (OG5_128727)

Species Accession Gene Product
Arabidopsis thaliana AT4G08690   Sec14p-like phosphatidylinositol transfer family protein
Arabidopsis thaliana AT4G36640   sec14p-like phosphatidylinositol transfer protein
Arabidopsis thaliana AT1G75170   Sec14p-like phosphatidylinositol transfer family protein
Babesia bovis BBOV_II004340   conserved hypothetical protein
Candida albicans CaO19.1027   lipid metabolism, MDR, regulates P'lipase D
Candida albicans CaO19.8629   lipid metabolism, MDR, regulates P'lipase D
Cryptosporidium hominis Chro.60122   CRAL/TRIO cell signalling protein
Cryptosporidium parvum cgd6_950   Pdr17p-like Sec14 domain containing protein
Dictyostelium discoideum DDB_G0269182   cellular retinaldehyde-binding/triple function domain-containing protein
Dictyostelium discoideum DDB_G0293606   cellular retinaldehyde binding/alpha-tocopherol transport family protein
Echinococcus granulosus EgrG_001146700   retinaldehyde binding protein
Echinococcus multilocularis EmuJ_001146700   retinaldehyde binding protein
Leishmania braziliensis LbrM.34.3490   hypothetical protein, conserved
Leishmania donovani LdBPK_353610.1   CRAL/TRIO, N-terminal domain/CRAL/TRIO domain containing protein, putative
Leishmania donovani LdBPK_301680.1   CRAL/TRIO domain containing protein, putative
Leishmania infantum LinJ.30.1680   hypothetical protein, conserved
Leishmania infantum LinJ.35.3610   hypothetical protein, conserved
Leishmania major LmjF.30.1680   hypothetical protein, conserved
Leishmania major LmjF.35.3560   hypothetical protein, conserved
Leishmania mexicana LmxM.29.1680   hypothetical protein, conserved
Leishmania mexicana LmxM.34.3560   hypothetical protein, conserved
Neospora caninum NCLIV_063230   hypothetical protein
Neospora caninum NCLIV_021550   hypothetical protein
Oryza sativa 4333953   Os03g0724100
Oryza sativa 4326204   Os01g0264700
Saccharomyces cerevisiae YNL231C   Pdr16p
Saccharomyces cerevisiae YNL264C   Pdr17p
Schistosoma japonicum Sjp_0303170   similar to Uncharacterized protein C23B6.04c, putative
Schistosoma mansoni Smp_158620   retinaldehyde binding protein-related
Schmidtea mediterranea mk4.003356.02   Retinaldehyde binding protein-related
Trypanosoma brucei gambiense Tbg972.9.7080   hypothetical protein, conserved
Trypanosoma brucei Tb927.9.11820   CRAL/TRIO domain containing protein, putative
Trypanosoma congolense TcIL3000_9_4810   hypothetical protein, conserved
Trypanosoma cruzi TcCLB.510667.10   CRAL/TRIO domain containing protein, putative
Trypanosoma cruzi TcCLB.511751.160   hypothetical protein, conserved
Trypanosoma cruzi TcCLB.507011.30   CRAL/TRIO domain containing protein, putative
Trypanosoma cruzi TcCLB.507023.70   hypothetical protein, conserved
Toxoplasma gondii TGME49_203390   CRAL/TRIO domain-containing protein
Toxoplasma gondii TGME49_246330   CRAL/TRIO domain-containing protein
Theileria parva TP04_0548   hypothetical protein, conserved

Essentiality

TGME49_203390 has direct evidence of essentiality
Gene/Ortholog Organism Phenotype Source Study
Tb09.211.2940 Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (3 days) alsford
Tb09.211.2940 Trypanosoma brucei significant gain of fitness in bloodstream forms (6 days) alsford
Tb09.211.2940 Trypanosoma brucei significant gain of fitness in procyclic forms alsford
Tb09.211.2940 Trypanosoma brucei significant gain of fitness in differentiation of procyclic to bloodstream forms alsford
TGME49_203390 this record Toxoplasma gondii Essentiality uncertain sidik
TGME49_246330 Toxoplasma gondii Essentiality uncertain sidik
Show/Hide essentiality data references
  • nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource
  • neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs
  • gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
  • alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924
  • plasmo Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Bushell, Ellen, et al. "Functional profiling of a Plasmodium genome reveals an abundance of essential genes." Cell 170.2 (2017): 260-272.
  • sidik A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Sidik, Saima M., et al. "A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes." Cell 166.6 (2016): 1423-1435.
  • blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930
  • goodall The Essential Genome of Escherichia coli K-12 (Transposon directed high-throughput mutagenesis) Goodall, Emily CA, et al. "The essential genome of Escherichia coli K-12." mBio 9.1 (2018): e02096-17.
  • shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan
  • wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170
  • keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection
  • yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database

Phenotypes and Validation (curated)

We have no manually annotated phenotypes for this target. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets
Obtained from network model
No druggable targets predicted through repurposing network model

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

No literature references available for this target.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier TGME49_203390 (Toxoplasma gondii), CRAL/TRIO domain-containing protein
Title for this comment
Comment